ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)Newsfile Corp • 08/01/20
SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)Business Wire • 07/30/20
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey HighlightsBusiness Wire • 07/29/20
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020Business Wire • 07/22/20
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related PsychosisBusiness Wire • 07/20/20
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive DisorderBusiness Wire • 07/20/20
Stock Upgrades: Acadia Pharmaceuticals Shows Rising Relative StrengthInvestors Business Daily • 07/08/20
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Hosts 2020 Annual Meeting of Stockholders (Transcript)Seeking Alpha • 06/23/20
ACADIA HEALTHCARE PARTNERS WITH COVENANT HEALTH ON SIGNIFICANT, COMPREHENSIVE NEW PROJECT TO ENHANCE BEHAVIORAL HEALTH SERVICES IN EAST TENNESSEEGlobeNewsWire • 06/02/20